Healthy Living South Dakota: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living South Dakota.

Press releases published on November 4, 2026

Nov. 4, 2026

Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)

Indeterminate GlobeNewswire

Nov. 4, 2026

Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC

Indeterminate GlobeNewswire

Nov. 4, 2026

Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome

Indeterminate GlobeNewswire

Nov. 4, 2026

Electra Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference in London

Indeterminate GlobeNewswire

Nov. 4, 2026

NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments

Indeterminate GlobeNewswire

Nov. 4, 2026

Noom Names Leading Awe Researcher Dacher Keltner as Advisor, Announces New National Awe Day

Indeterminate GlobeNewswire

Nov. 4, 2026

Phathom Pharmaceuticals to Participate in November Investor Conferences

Indeterminate GlobeNewswire

Nov. 4, 2026

Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026

Indeterminate GlobeNewswire

Nov. 4, 2026

Processa Pharmaceuticals Announces Key Leadership Appointments

Indeterminate GlobeNewswire

Nov. 4, 2026

Sutro Biopharma to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Nov. 4, 2026

Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting

Indeterminate GlobeNewswire

Nov. 4, 2026

Jasper Therapeutics Announces 1-for-30 Reverse Stock Split

Indeterminate GlobeNewswire

Nov. 4, 2026

BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Indeterminate GlobeNewswire

Nov. 4, 2026

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights

Indeterminate GlobeNewswire

Nov. 4, 2026

Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026

Indeterminate GlobeNewswire

Nov. 4, 2026

Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026

Indeterminate GlobeNewswire

Nov. 4, 2026

Neuronetics Reports Third Quarter 2026 Financial and Operating Results

Indeterminate GlobeNewswire

Nov. 4, 2026

Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference

Indeterminate GlobeNewswire

Nov. 4, 2026

Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum

Indeterminate GlobeNewswire

Nov. 4, 2026

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

Indeterminate GlobeNewswire